DOI: 10.1097/01.jcp.0000264981.94614.54
,
,
PMID: 17414263
Issn Print: 0271-0749
Publication Date: 2007/04/01
Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
Aripiprazole is a derivative of quinolone, which acts as a partial dopamine D2 agonist. It has a partial agonist activity on serotonin 5-HT1A receptors and an antagonistic activity on 5-HT2A receptors.1 Emergence or exacerbation of obsessive-compulsive symptoms (OCS) during treatment with atypical antipsychotics has been extensively described in literature.2,3 However, to our knowledge, this is the first report of worsening of OCS under aripiprazole.
